SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
DARE

Dare Bioscience, Inc. (NASDAQ:DARE)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.41-$0.04 (-9.87%)
 
Market cap
$8.01M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 10, 2014
Market Cap$8.01M-75.8%
Revenue (ttm)$1.41M+2570.3%
Net Income-$10.58M+39.4%
EPS-$0.69+63.3%
Shares Out19.67M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume173,237
Open$0.44
Previous Close$0.45
Day's Range$0.41 - $0.44
52-Week Range$0.41 - $3.78
Beta1.15
AnalystsBuy
Price Target$1.50(+268.19%)
Earnings DateMar 25, 2027
-9.29% (1D)
No price history available.

About DARE

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Address
3655 Nobel Drive, San Diego, CA, 92122, US
Market Cap
8 million
Employees
23
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$382.26
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From DARE’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-9.87%
5 Days
-41.30%
1 Month
-40.78%
6 Months
-83.10%
1 Year
-75.75%

$DARE stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in DARE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by DARE's directors and management

Net Shares Purchased by Insiders−900−45002025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

DARE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

DARE Revenue by Segment

$1.34MTotal
Direct program costs:$1.03M76.28%
Indirect costs:$318.91K23.72%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New DARE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to DARE from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in DARE

VTIVanguard Morningstar Total Stock Market ETF$259.93K
VXFVanguard Extended Market ETF$112.90K
IWCiShares Micro-Cap ETF$18.58K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from DARE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
58

News check: Q3 revenue miss offset by first product sales milestone, grant funding, and pipeline progress; mixed results with early commercial traction.

Recent Insider Activity

Buys
0
Sells
1
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.